MD Anderson researchers present encouraging results of early-stage clinical trials at 2022 ASCO Annual Meeting
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
The findings, presented today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight advances researchers are making to develop more effective therapies for patients...
Ultrasound-guided microbubbles boost immunotherapy efficacy
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates...
MD Anderson and Community Health Network announce partnership to create fully integrated cancer program
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement...
Therapies targeting DNA damage response show promising antitumor activity
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor elimusertib and PARP inhibitor AZD5305 — are safe and clinically beneficial in treating patients with advanced solid tumors. Principal investigator Timothy Yap, M.B.B.S., Ph.D., associate professor of Investigational Cancer Therapeutics, today presented new data from the trials at the American...
MD Anderson Research Highlights: SGO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
MD Anderson renews partnership with Banner Health
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner...
Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...
Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy...
Anil Sood, M.D., elected to the National Academy of Medicine
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
ATR inhibitor RP-3500 demonstrates safety and early clinical benefit
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...